By Lina carolina 
Researchers at the Francis Crick Institute, in collaboration with the UCL Cancer Institute and University College London Hospitals (UCLH), have unveiled a groundbreaking diagnostic tool named ORACLE that demonstrates a superior ability to predict lung cancer survival at the point of diagnosis compared to existing clinical risk factors. This development holds significant promise for optimizing treatment decisions, particularly for patients diagnosed with early-stage (Stage 1) lung cancer, potentially mitigating the risks of cancer recurrence and metastasis. The findings, published in the esteemed journal Nature Cancer, represent a crucial step towards more personalized and effective lung cancer management.
A Leap Forward in Predictive Accuracy
The ORACLE test was rigorously evaluated within the TRACERx study, a comprehensive initiative funded by Cancer Research UK. In a cohort of 158 lung cancer patients, ORACLE consistently outperformed conventional clinical standards, including tumor staging, in its capacity to forecast patient survival. This enhanced predictive power is attributed to ORACLE’s innovative approach to analyzing the complex genetic landscape of tumors.
Traditional methods of tumor analysis often involve extracting tissue samples that represent less than 1% of the entire tumor. This limited sampling can be problematic because the genetic makeup of a tumor can vary significantly across different regions. ORACLE addresses this limitation by examining gene expression levels across the entirety of the tumor, providing a more comprehensive biological snapshot. By identifying genes that are expressed at high or low levels in any part of the tumor, ORACLE offers a more nuanced understanding of the tumor’s aggressive potential.
Addressing the Unmet Need in Early-Stage Lung Cancer
The implications of ORACLE are particularly profound for individuals diagnosed with Stage 1 lung cancer. These patients typically undergo surgery as their primary treatment, often without adjuvant chemotherapy. However, a significant proportion, approximately one in four, experience cancer recurrence. This suggests that a subset of these patients might have benefited from more intensive monitoring or chemotherapy from the outset. ORACLE’s ability to identify those at higher risk of recurrence, even at this early stage, could enable clinicians to proactively tailor treatment strategies.
The research highlights that ORACLE can pinpoint Stage 1 lung cancer patients who have a lower probability of survival and may therefore benefit from the addition of chemotherapy alongside surgery. This level of personalized risk stratification was not achievable with the clinical standards currently in use for this patient group.
Unraveling Tumor Heterogeneity and Spread Potential
Beyond survival prediction, the study revealed that elevated ORACLE risk scores were intrinsically linked to specific regions within the tumor that exhibited a greater propensity for metastasis. This discovery offers valuable insights into the biological mechanisms driving cancer spread and could potentially lead to the development of novel strategies to inhibit this process.
Predicting Treatment Response: A New Frontier
Furthermore, the research extended to evaluating the efficacy of existing and potential lung cancer drugs. By analyzing the response to 359 current and experimental therapies, the team discovered that patients with high ORACLE risk scores demonstrated a more favorable response to certain chemotherapy regimens, notably platinum-based drugs such as cisplatin.
This enhanced response is thought to be a consequence of the biological characteristics of tumor regions associated with high ORACLE scores. These regions are often characterized by chromosomal instability, a state of DNA imbalance that makes cancer cells particularly vulnerable to the DNA-damaging effects of platinum drugs. Coincidentally, recent work from the same laboratory has identified alterations in the FAT1 gene as a driver of chromosomal instability, a factor that ORACLE is designed to detect. This convergence of findings strengthens the rationale behind ORACLE’s predictive capabilities.
The Path Forward: Clinical Validation and Implementation
The immediate next steps for the research team involve a critical phase of validation. They plan to conduct comparative studies to assess whether individuals with high ORACLE scores who receive enhanced surveillance or chemotherapy experience improved survival outcomes compared to those undergoing standard care. This crucial step will determine the real-world impact of ORACLE in improving patient prognosis, even for those diagnosed at the earliest stages of lung cancer.
Dr. Dhruva Biswas, Translation Fellow at the Crick and co-first author of the study, emphasized the transformative potential of ORACLE. "ORACLE can now predict survival rates in patients diagnosed at the earliest stage," Dr. Biswas stated. "If validated in larger cohorts of patients with lung cancer, doctors could one day use ORACLE to help make informed treatment decisions, bringing lessons from cancer evolution into the clinic."
Yun-Hsin Liu, Research Assistant at the UCL Cancer Institute and co-first author, elaborated on the study’s objectives. "We wanted to build on the previous work developing ORACLE and show that it can predict survival at the point of a lung cancer diagnosis," Ms. Liu explained. "We’ve also shown that it can predict who would benefit from certain types of chemotherapy drugs or if someone’s cancer is likely to spread, giving a holistic measure of how a patient’s cancer might progress and respond."
Professor Charles Swanton, Deputy Clinical Director and Head of the Cancer Evolution and Genome Instability Laboratory at the Crick, and co-senior author, underscored the urgency of developing better diagnostic tools for lung cancer, which remains the leading cause of cancer-related death globally. "Lung cancer is the leading cause of cancer-related death throughout the world, so it’s clear we need better markers to accurately classify tumours and predict who is at high risk," Professor Swanton commented. "We’re now working with the Translation team at the Crick and industry partners to progress ORACLE into a test which could hopefully be used in the clinic as soon as possible."
Paul Mercer, Head of Industry Partnerships in the Crick Translation team, highlighted the significance of translating complex scientific understanding into practical clinical tools. "This is an important step forward, translating our understanding of the infinite complexities of lung cancer mutation into a diagnostic tool, prioritising patients for the most effective therapies," Mr. Mercer remarked. "We look forward to working with partners to take this work forward and maximise patient benefit from ORACLE."
A Beacon of Hope from Cancer Research UK
Dani Edmunds, Science Engagement Manager at Cancer Research UK, expressed optimism regarding the potential of ORACLE to advance lung cancer treatment. "In the last 50 years, cancer survival has doubled in the UK. However, progress has not been equal across all types of cancer. Although survival for lung cancer has improved since the 1970s, it’s still one of the most challenging cancers to treat," Ms. Edmunds stated.
She further added, "New tests to predict lung cancer’s behaviour could help doctors tailor treatment strategies to each person’s condition, giving the best chance of a successful outcome. This research reflects Cancer Research UK’s commitment to tackle this hard-to-treat cancer. While ORACLE still needs testing in larger-scale trials, these initial results show it could take us a step closer to more personalised approaches to treating lung cancer, so more people live longer, better lives."
The study received vital support from the National Institute for Health and Care Research UCLH Biomedical Research Centre, underscoring the collaborative and multi-institutional effort behind this significant advancement.
Background and Broader Implications
Lung cancer has historically presented a formidable challenge in oncology due to its complex biology, often late diagnosis, and the heterogeneity of tumor responses to treatment. For decades, treatment decisions for lung cancer have largely relied on established pathological staging and clinical factors such as patient age, performance status, and the presence of comorbidities. While these factors have provided a framework for care, they often fail to capture the individual nuances of a patient’s disease, leading to suboptimal treatment outcomes for some.
The advent of molecular profiling has begun to revolutionize cancer care, identifying specific genetic mutations that can be targeted by precision therapies. However, even within specific molecular subtypes, tumor heterogeneity—the presence of diverse cell populations within a single tumor—can lead to treatment resistance and disease relapse. The TRACERx study, in which the ORACLE test was evaluated, itself represents a landmark effort to unravel the evolutionary dynamics of lung cancer, tracking tumor genetic changes over time and in response to treatment across a large cohort of patients. The ORACLE test emerges from this deep understanding of cancer evolution, seeking to translate complex biological insights into actionable clinical information.
The implications of ORACLE extend beyond just predicting survival. Its ability to identify tumor regions prone to spread could pave the way for the development of therapies that specifically target these metastatic hotspots. Furthermore, the correlation between high ORACLE scores and improved response to platinum-based chemotherapy suggests a potential for de-escalating treatment for patients predicted to have good outcomes with less aggressive regimens, while concurrently intensifying treatment for those identified as high-risk. This judicious use of resources and treatment intensity could significantly improve the quality of life for patients and reduce the burden of overtreatment.
The journey from laboratory discovery to clinical implementation is often lengthy and complex. The current findings represent a critical proof-of-concept. The next phase of clinical trials will be pivotal in demonstrating ORACLE’s utility in a real-world clinical setting and establishing its cost-effectiveness and integration into standard diagnostic pathways. Success in these trials could position ORACLE as a vital tool in the fight against lung cancer, offering a more precise and personalized approach that could significantly improve the lives of countless patients worldwide. The ongoing collaboration between academic institutions and industry partners is crucial to accelerating this transition, ensuring that cutting-edge research translates into tangible benefits for patients.